Flexion Therapeutics Inc (FLXN) 12.52 $FLXN
Flexion Therapeutics Reports First-Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Key Highlights
Flexion Therapeutics to Report First Quarter 2014 Financial Results on May 8, 2014
GlobeNewswire - Thu May 01, 7:31AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first quarter 2014 financial results on Thursday, May 8, 2014, at 4:30 p.m. ET.
Flexion Therapeutics Initiates a Phase 2b Confirmatory Dose-Ranging Trial With Lead Compound FX006
GlobeNewswire - Wed Apr 30, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA). It is designed to provide prolonged pain relief for the treatment of mild to moderate OA of the knee, while avoiding untoward systemic effects associated with immediate release steroids.
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Flexion Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman's presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place April 8-9, 2014, at The Westin New York Grand Central.
Flexion Reports Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 27, 7:14AM CDT
- Strong cash position bolstered with additional $75 million from IPO -
Flexion Therapeutics to Report Year-End 2013 Earning Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:00PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2013 financial results on Thursday, March 27, 2014, at 4 p.m. ET.
Flexion Therapeutics to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 8:22AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 34 Annual Cowen Health Care Conference. Dr. Clayman's presentation is scheduled for March 3, 2014, at 4:50 p.m. Eastern Time. The Conference will take place March 3-5, 2014, at The Boston Marriott Copley Place.
Flexion Therapeutics reports IPO of 5.75m shares of common stock, including underwriters' option
M2 - Wed Feb 19, 5:14AM CST
Pharmaceutical company Flexion Therapeutics Inc (NasdaqGM:FLXN) said on Tuesday that it has completed the initial public offering of 5,750,000 shares of its common stock.
Flexion Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 18, 4:00PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the closing of its initial public offering of 5,750,000 shares of its common stock at an initial public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. Flexion offered all of the shares of common stock. The aggregate net proceeds to Flexion, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.3 million.
Talmer, Eagle Pharma, Flexion up in trading debuts
AP - Wed Feb 12, 10:17AM CST
NEW YORK (AP) — Three companies, a bank and two drug developers, making their market debuts are trading higher on Wednesday on the Nasdaq.
Flexion Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Feb 11, 5:03PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $13.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "FLXN" on February 12, 2014. Flexion is offering all of the shares of common stock. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is expected to close on February 18, 2014, subject to customary closing conditions.
Flexion Therapeutics Reports First-Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Key Highlights
Flexion Therapeutics to Report First Quarter 2014 Financial Results on May 8, 2014
GlobeNewswire - Thu May 01, 7:31AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first quarter 2014 financial results on Thursday, May 8, 2014, at 4:30 p.m. ET.
Flexion Therapeutics Initiates a Phase 2b Confirmatory Dose-Ranging Trial With Lead Compound FX006
GlobeNewswire - Wed Apr 30, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA). It is designed to provide prolonged pain relief for the treatment of mild to moderate OA of the knee, while avoiding untoward systemic effects associated with immediate release steroids.
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Flexion Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman's presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place April 8-9, 2014, at The Westin New York Grand Central.
Flexion Reports Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 27, 7:14AM CDT
- Strong cash position bolstered with additional $75 million from IPO -
Flexion Therapeutics to Report Year-End 2013 Earning Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:00PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2013 financial results on Thursday, March 27, 2014, at 4 p.m. ET.
Flexion Therapeutics to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 8:22AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 34 Annual Cowen Health Care Conference. Dr. Clayman's presentation is scheduled for March 3, 2014, at 4:50 p.m. Eastern Time. The Conference will take place March 3-5, 2014, at The Boston Marriott Copley Place.
Flexion Therapeutics reports IPO of 5.75m shares of common stock, including underwriters' option
M2 - Wed Feb 19, 5:14AM CST
Pharmaceutical company Flexion Therapeutics Inc (NasdaqGM:FLXN) said on Tuesday that it has completed the initial public offering of 5,750,000 shares of its common stock.
Flexion Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 18, 4:00PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the closing of its initial public offering of 5,750,000 shares of its common stock at an initial public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. Flexion offered all of the shares of common stock. The aggregate net proceeds to Flexion, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.3 million.
Talmer, Eagle Pharma, Flexion up in trading debuts
AP - Wed Feb 12, 10:17AM CST
NEW YORK (AP) — Three companies, a bank and two drug developers, making their market debuts are trading higher on Wednesday on the Nasdaq.
Flexion Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Feb 11, 5:03PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $13.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "FLXN" on February 12, 2014. Flexion is offering all of the shares of common stock. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is expected to close on February 18, 2014, subject to customary closing conditions.
